Drug or treatment

Sintilimab clinical trials

• 124Clinical trials
• 1Country

Newest trials

All recruiting trials (124)

• Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer

  This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07840677

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

• Sintilimab with NALIRIFOX or GP as first-line treatment for metastatic biliary tract cancer

  This study tests whether adding sintilimab to either NALIRIFOX or gemcitabine‑cisplatin can help people with metastatic biliary tract cancer who have not had prior systemic therapy.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07831993

• Liposomal irinotecan with 5-FU/LV and sintilimab plus SBRT for unresectable biliary tract cancer

  This trial tests whether combining liposomal irinotecan, 5-FU/LV, and sintilimab, followed by SBRT, can help patients with unresectable locally advanced biliary tract cancer become eligible for surgery or slow disease progression.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07797816

• Sintilimab Plus Hypofractionated Radiotherapy Then Chemoradiotherapy for Locally Advanced Head and Neck Cancer

  This study tests whether giving sintilimab with a short, high-dose radiotherapy course followed by standard chemoradiotherapy helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07781072

• Bevacizumab, sintilimab, cetuximab and irinotecan in refractory RAS wild-type metastatic colorectal cancer

  This trial tests whether adding sintilimab to a cetuximab and irinotecan backbone, with or without bevacizumab, helps patients with heavily pretreated metastatic colorectal cancer that has RAS wild-type tumors.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07722754

• QLS31905 plus CAPOX vs sintilimab plus CAPOX as first-line treatment for gastric/GEJ cancer

  This phase 3 trial tests whether QLS31905 with CAPOX works as well as or better than sintilimab with CAPOX for first-line treatment in CLDN18.2-positive, PD-L1 CPS < 5, HER2-negative unresectable or metastatic gastric/GEJ cancer.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT07716449

• Sintilimab plus IMRT and capecitabine as an alternative to mitomycin in limited-stage anal squamous cell carcinoma

  This trial tests whether replacing mitomycin with the PD-1 inhibitor sintilimab during chemoradiotherapy is at least as effective in achieving complete response after treatment for limited-stage anal squamous cell carcinoma.

  Recruiting at 2 sites Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 1 other locations · NCT07692152

• SBRT followed by a multi-drug immunotherapy and chemo regimen for locally advanced pancreatic cancer

  This trial tests whether giving SBRT followed by a combination of ipilimumab, sintilimab, nab-paclitaxel, and gemcitabine helps people with locally advanced pancreatic cancer.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07683221

• Sintilimab with chemotherapy, with or without ipilimumab, for resectable stomach/GEJ cancer

  A randomized trial tests whether adding sintilimab (and possibly ipilimumab) to standard chemotherapy around surgery helps people with resectable stomach or gastroesophageal junction cancer.

  Recruiting Phase 2/3 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Guangzhou, Guangdong · NCT07643623

• HAIC vs. TACE plus sintilimab and bevacizumab for intermediate HCC with high tumor burden

  This trial tests whether FOLFOX-HAIC plus immunotherapy and anti-angiogenic therapy works better than TACE plus the same systemic therapy for adults with intermediate-stage hepatocellular carcinoma with tumors beyond Up-To-Seven criteria.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07594340

• JS107 plus toripalimab and chemotherapy as first-line treatment for CLDN18.2-positive gastric cancer

  This trial tests whether JS107 added to toripalimab and XELOX is better than a similar regimen with sintilimab for patients with untreated, CLDN18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma.

  Recruiting Phase 3 NingBo Junyan Hongshi Biosciences Co., Ltd · Guangzhou, Guangdong · NCT07584135

• Sintilimab plus anlotinib and a taxane for recurrent or metastatic nasopharyngeal carcinoma

  This trial will test whether adding the PD‑1 drug sintilimab and the oral anti‑angiogenic anlotinib to a taxane chemotherapy helps adults with recurrent or metastatic nasopharyngeal carcinoma who have already failed platinum chemotherapy and/or prior anti‑PD‑1/PD‑L1 therapy.

  Recruiting Phase 2 Sun Yat-sen University · Zhuhai, Guangdong · NCT07581821

• Combining two immunotherapies, a bevacizumab biosimilar, and liver-artery chemotherapy to shrink advanced liver cancer for possible surgery

  This treatment will try a combo of two immune drugs (sintilimab and ipilimumab N01), a bevacizumab biosimilar, and hepatic arterial infusion chemotherapy to shrink unresectable intermediate-to-advanced hepatocellular carcinoma so more patients can become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07560488

• Combination therapy with BRII-5395, sintilimab, and bevacizumab in advanced HBV-related hepatocellular carcinoma

  This early-phase study tests BRII-5395 together with two approved cancer drugs to see if it is safe and tolerable in people with advanced HBV-related liver cancer.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07557251

• CVM-1118 plus sintilimab infusions and TACE for incurable non-metastatic liver cancer

  This trial will test whether combining oral CVM-1118 with sintilimab infusions and TACE helps people with incurable, non-metastatic hepatocellular carcinoma.

  Recruiting at 2 sites Phase 2 TaiRx, Inc. · Fuzhou, Fujian and 1 other locations · NCT07521852

• Chidamide, sintilimab and bevacizumab as second-line treatment for advanced extrapulmonary neuroendocrine carcinoma

  This trial tests whether the combination of chidamide, sintilimab, and bevacizumab can shrink tumors in adults with advanced extrapulmonary neuroendocrine carcinoma who progressed after first-line therapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07518602

• Sintilimab + ipilimumab N01 with cetuximab and dabrafenib for MSS BRAF V600E metastatic colorectal cancer

  This trial will test whether combining the immunotherapies sintilimab and ipilimumab N01 with cetuximab and dabrafenib helps people with microsatellite-stable, BRAF V600E metastatic colorectal cancer live longer or have better tumor control.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07506109

• Intensified versus conversion therapy for advanced liver cancer after first-line bevacizumab plus sintilimab fails

  This study tests whether adding lenvatinib or switching to regorafenib plus a PD-1 blocker works better and is safe for adults with advanced hepatocellular carcinoma whose cancer progressed after first-line bevacizumab plus sintilimab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07501351

• Sintilimab plus SOX chemotherapy versus SOX alone after surgery for stomach or gastroesophageal junction adenocarcinoma

  This trial will test whether adding sintilimab to SOX chemotherapy after surgery helps people with stage IIIC or dMMR/MSI‑H stage IIIA/IIIB stomach or gastroesophageal junction cancer stay disease‑free longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07492615

• Neoadjuvant fulzerasib followed by sintilimab plus platinum-doublet chemotherapy for resectable KRAS G12C-mutant NSCLC

  This will test whether giving fulzerasib first, then sintilimab with platinum-doublet chemotherapy before surgery helps people with resectable KRAS G12C‑mutant stage IB–IIIA non‑small cell lung cancer.

  Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University · Beijing and 2 other locations · NCT07492342

• IBI310 with sintilimab as first-line treatment for hepatocellular carcinoma

  This trial will test whether combining IBI310 with sintilimab works and is safe as a first-line option for people with advanced or metastatic hepatocellular carcinoma who have not received systemic therapy and are not candidates for curative local treatments.

  Recruiting Phase 2/3 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hefei, Anhui and 1 other locations · NCT07490262

• IBI343 with sintilimab and SOX before and during surgery for resectable locally advanced gastric or GEJ cancer

  A phase II trial tests whether adding IBI343 to sintilimab plus a SOX chemotherapy regimen around surgery helps people with CLDN18.2-positive, locally advanced gastric or GEJ cancer who are candidates for curative D2 surgery.

  Recruiting Phase 2 Innovent Biologics (Suzhou) Co. Ltd. · Beijing, Beijing Municipality · NCT07483567

• Short-course radiation followed by liposomal irinotecan, oxaliplatin, capecitabine and sintilimab before surgery for high-risk rectal cancer

  This treatment plan tests whether a short course of radiation followed by six cycles of liposomal irinotecan, oxaliplatin, capecitabine and the immunotherapy drug sintilimab before surgery can shrink tumors and let some people with newly diagnosed high-risk, locally advanced rectal cancer avoid immediate surgery.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan · NCT07474103

• Becotatug vedotin plus sintilimab with chemoradiation for high-risk nasopharyngeal carcinoma

  This trial tests whether adding becotatug vedotin before treatment and giving sintilimab with chemoradiation helps people with high‑risk locally advanced nasopharyngeal carcinoma live longer and avoid recurrence.

  Recruiting Phase 3 First Affiliated Hospital of Guangxi Medical University · Nanning, Guangxi · NCT07459296

• GV20-0251 with sintilimab given before surgery for resectable head and neck cancer

  This treatment combination will be given before surgery to test safety and early anti-tumor activity in adults with resectable, locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 1 West China Hospital · Chengdu · NCT07457281

• TACE with sintilimab, bevacizumab, and ipilimumab N01 for advanced liver cancer

  This trial tries a combination of TACE with sintilimab and bevacizumab plus a single dose of ipilimumab N01 given at different times to see if it is safe and helps people with advanced hepatocellular carcinoma whose tumors cannot be removed.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07422753

• Thiotepa with pirtobrutinib and sintilimab for frail or relapsed/refractory CNS lymphoma

  This treatment combines thiotepa with pirtobrutinib and sintilimab for adults who are frail or whose primary or secondary central nervous system lymphoma has relapsed or not responded to prior therapy.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07416890

• Anti-CTLA-4 plus sintilimab and chemotherapy before surgery for resectable Stage II–III NSCLC

  This trial will test whether adding an anti-CTLA-4 antibody (IBI310) to sintilimab plus chemotherapy before surgery helps people with PD-L1–negative, resectable Stage II–III non-small cell lung cancer.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07410975

• Sintilimab plus chemotherapy after surgery for mucosal melanoma

  This test will see if adding the immunotherapy drug sintilimab to standard chemotherapy after surgery helps people with PD-L1–positive mucosal melanoma stay cancer-free longer.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07400302

• Anlotinib plus sintilimab as first treatment for advanced colorectal cancer without liver metastases

  This study will see if taking anlotinib together with sintilimab as the first treatment helps adults with advanced colorectal cancer that has spread outside the liver who cannot or choose not to have standard chemotherapy.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07398326

• Sintilimab with chemotherapy before and after surgery for locally advanced oral squamous cell carcinoma

  This trial will test whether adding sintilimab to chemotherapy before and after surgery helps people with locally advanced oral squamous cell carcinoma have fewer recurrences and better survival.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07371611

• Neoadjuvant chemotherapy with sintilimab and bevacizumab for triple-negative breast cancer

  This trial will try adding the immunotherapy drug sintilimab and the blood‑vessel blocker bevacizumab to pre-surgery chemotherapy for women with stage II–III triple‑negative breast cancer to see if more tumors disappear completely before surgery.

  Recruiting at 2 sites Phase 2 First Affiliated Hospital of Zhejiang University · Hefei and 1 other locations · NCT07351487

• Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL

  This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.

  Recruiting at 3 sites Phase 2 Tongji Hospital · Xiamen, Fujian and 3 other locations · NCT07350850

• Sintilimab plus a bevacizumab biosimilar as adjuvant therapy after surgery for ruptured hepatocellular carcinoma

  This trial will test whether giving sintilimab together with a bevacizumab biosimilar after curative surgery can lower recurrence in adults who had a ruptured hepatocellular carcinoma and complete resection.

  Recruiting at 3 sites Phase 2 Ruijin Hospital · Sanming, Fujian and 3 other locations · NCT07331883

• Sintilimab plus bevacizumab biosimilar before surgery for resectable liver cancer

  This trial will test whether giving sintilimab together with a bevacizumab biosimilar before surgery helps people with resectable hepatocellular carcinoma beyond the Milan criteria.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07324824

• Neoadjuvant SBRT then sintilimab with chemotherapy for N3-positive locally advanced NSCLC

  This approach tests whether focused radiation to the primary lung tumor followed by two cycles of sintilimab plus platinum-based chemotherapy before surgery can shrink N3-positive locally advanced non-small cell lung cancer and enable curative surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07309952

• Sintilimab added to SOX chemotherapy after surgery for PD-L1–positive pN3 gastric cancer

  This trial will test whether adding the PD-1 blocker sintilimab to standard SOX chemotherapy after surgery helps people with PD-L1–positive, pathologic N3 gastric cancer stay cancer-free longer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07263386

• Conversion therapy using disitamab vedotin (RC48), sintilimab, and SOX for HER2 IHC 1+ or 2+ unresectable gastric cancer

  This trial will test whether combining disitamab vedotin (RC48), the immunotherapy sintilimab, and SOX chemotherapy can shrink tumors enough to allow surgery in people with initially unresectable HER2 IHC 1+ or 2+ gastric cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07194005

• Post-surgery radiotherapy plus sintilimab versus TACE for liver cancer with narrow surgical margins

  This trial will try to see if adding radiotherapy and the immunotherapy drug sintilimab after curative liver cancer surgery prevents recurrence better than TACE in patients with narrow surgical margins and other high-risk features.

  Recruiting Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07186621

• Combining PD‑1 immunotherapy (sintilimab) with platinum‑doublet chemotherapy and adaptive radiotherapy for stage III non‑small cell lung cancer

  This study tests whether adding the PD‑1 drug sintilimab to standard platinum‑doublet chemotherapy plus adaptive radiotherapy helps people with unresectable stage III non‑small cell lung cancer.

  Recruiting at 4 sites Phase 2 The Third Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07138755

• Adaptive adjuvant sintilimab treatment guided by MRD for resected Stage II–IIIB NSCLC

  This trial tests whether using postoperative blood MRD tests to guide adjuvant sintilimab helps people with resected Stage II–IIIB NSCLC who did not achieve a complete response after neoadjuvant chemo‑immunotherapy.

  Recruiting at 2 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 1 other locations · NCT07120698

• Relmacabtagene autoleucel plus sintilimab for relapsed or refractory CD19‑positive B‑cell lymphoma

  This trial will test whether giving relmacabtagene autoleucel followed by the PD‑1 drug sintilimab helps adults with relapsed or refractory CD19‑positive large B‑cell, follicular, or mantle cell lymphoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou and 2 other locations · NCT07077512

• First-line immunotherapy plus chemotherapy in extensive-stage small cell lung cancer

  This study tests whether adding Tafolecimab and Sintilimab to standard chemotherapy can help people with extensive-stage small cell lung cancer.

  Recruiting at 4 sites Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Changsha, Hunan and 4 other locations · NCT07061535

• IBI343 plus sintilimab and chemotherapy for CLDN18.2-positive gastric or gastroesophageal junction cancer

  This trial tests IBI343 combined with sintilimab and standard chemotherapy as a first-line treatment for adults with CLDN18.2-positive, HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07025889

• Comparing two treatment combinations for advanced gastric cancer

  This study is testing if adding a new drug called apatinib to standard treatments can help people with advanced gastric cancer get better results and stay safe during treatment.

  Recruiting at 4 sites Phase 3 Lanzhou University Second Hospital · Lanzhou, Gansu and 3 other locations · NCT06925243

• Combination treatment for large liver cancer with portal vein involvement

  This study is testing a new combination treatment for people with large liver cancer that has spread to the portal vein to see if it works better than the standard treatment.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904183

• Combining sintilimab, lenvatinib, and HAIC for treating borderline resectable liver cancer before surgery

  This study is testing if a combination of three treatments can help people with borderline resectable liver cancer do better in surgery compared to having surgery right away.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06904014

• Combining HAIC with Sintilimab and Bevacizumab for Advanced Liver Cancer

  This study is testing if a new combination of chemotherapy and two other drugs can help people with advanced liver cancer feel better compared to using just the two drugs alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06860490

• Sintilimab combined with AVD chemotherapy for treating pediatric Hodgkin lymphoma

  This study is testing if a new immunotherapy combined with standard chemotherapy can help children and teens with low-to-intermediate risk Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06848569

• Treatment for untreated extranodal NK/T-cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with untreated extranodal NK/T-cell lymphoma feel better and improve their chances of survival.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06824883

• Combining HAIC with Donafenib and Sintilimab for Liver Cancer Treatment

  This study is testing if a new combination of chemotherapy and medications can help people with liver cancer who are at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Fudan University · Fuzhou, Fujian and 2 other locations · NCT06812039

• Evaluating Sintilimab and Bevacizumab for Rectal Cancer Treatment

  This study is testing if a new combination of two drugs, sintilimab and bevacizumab, can improve treatment outcomes for people with rectal cancer who have had different previous therapies.

  Recruiting Phase 2 Xijing Hospital of Digestive Diseases · Xi'an, Shaanxi · NCT06808412

• Combination treatment of sintilimab and linperlisib for relapsed NK/T-cell lymphoma

  This study is testing a new combination of two drugs, sintilimab and linperlisib, to see if it can help people with relapsed NK/T-cell lymphoma who haven't had success with other treatments.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT06793956

• Combination treatment for advanced colorectal cancer

  This study is testing a new combination of treatments for advanced colorectal cancer to see if it can help patients live longer and feel better.

  Recruiting Phase 1/2 Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Shenzhen, Guangdong · NCT06776757

• ORIENT-31 plus targeted SBRT for EGFR‑mutant metastatic lung cancer after third‑generation EGFR‑TKI

  This study will test whether adding targeted stereotactic radiotherapy (SBRT) to the ORIENT-31 drug combination helps people with EGFR‑mutant metastatic non‑small cell lung cancer whose disease progressed after first‑line third‑generation EGFR‑TKIs.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06775743

• Treatment for advanced gastric cancer using BC001, Sintilimab, and XELOX

  This study is testing a new treatment combining BC001, Sintilimab, and XELOX to see if it helps people with advanced gastric cancer feel better and live longer.

  Recruiting Phase 1 Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06773312

• Oral trifluridine/tipiracil with bevacizumab and sintilimab, with or without targeted radiation, for advanced MSS/pMMR colorectal cancer after two or more prior treatments

  This trial will try oral trifluridine/tipiracil combined with bevacizumab and sintilimab, with or without focused radiation, in people with advanced MSS/pMMR colorectal cancer who have progressed after at least two prior therapies.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06764680

• Combining Sintilimab with Chemotherapy for Stage III Gastric Cancer Treatment

  This study is testing if combining a new drug called Sintilimab with chemotherapy can help people with stage III gastric cancer feel better after their surgery.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06761846

• Combination treatment for advanced pancreatic cancer

  This study is testing a new combination treatment for advanced pancreatic cancer to see if it helps patients who haven't had treatment before.

  Recruiting Phase 1/2 Fujian Provincial Hospital · Fuzhou, Fujian and 3 other locations · NCT06761027

• Sintilimab plus rituximab followed by R-CHOP for untreated primary mediastinal DLBCL

  This study will see if giving sintilimab with rituximab first, then switching to R-CHOP chemotherapy, helps people newly diagnosed with primary mediastinal diffuse large B‑cell lymphoma get better responses.

  Recruiting Phase 2 Sun Yat-sen University · Fuzhou, Fujian and 1 other locations · NCT06742502

• Combining XELOX chemotherapy, sintilimab, and hyperbaric oxygen therapy for advanced gastric cancer

  This study is testing a new combination of chemotherapy, an immune therapy, and oxygen treatment to see if it can help people with advanced stomach cancer feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan and 1 other locations · NCT06742411

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination of treatments for people with advanced HER2-positive gastric cancer to see if it works better than the standard chemotherapy options.

  Recruiting at 16 sites Phase 2 Qilu Hospital of Shandong University · Zhengzhou, Henan and 19 other locations · NCT06730373

• Combining low dose radiotherapy with immunotherapy and chemotherapy for lung cancer treatment

  This study is testing whether a combination of low dose radiation, immunotherapy, and chemotherapy can help people with stage II-III non-small cell lung cancer do better before surgery.

  Recruiting Phase 2 Anhui Provincial Cancer Hospital · Hefei, Anhui · NCT06714708

• Combining sintilimab with chemotherapy and radiotherapy for advanced esophageal cancer

  This study is testing if combining an immunotherapy drug called sintilimab with chemotherapy and radiation can help people with advanced esophageal cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT06709417

• Examining the relationship between Sintilimab levels and treatment outcomes in advanced gastric cancer patients

  This study is testing how the levels of Sintilimab in the blood affect treatment results and side effects for people with advanced gastric cancer.

  Recruiting Zhongda Hospital · Nanjing, Jiangsu · NCT06702683

• Neoadjuvant treatment for advanced colorectal cancer using Sintilimab

  This study tests if giving the immunotherapy drug Sintilimab before surgery can help people with advanced colorectal cancer have better outcomes and lower chances of their cancer coming back.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zheng'zhou, Henan · NCT06698757

• Combining Fruquintinib, Chidamide, and Sintilimab for Advanced Colorectal Cancer Treatment

  This study is testing a new combination of three drugs to see if it can help people with advanced colorectal cancer that hasn't improved with other treatments.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT06685276

• Treatment for advanced liver cancer using new drug combinations

  This study is testing whether a new combination of drugs can help people with advanced liver cancer live longer and feel better compared to another treatment option.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Hefei, Anhui · NCT06618664

• Combining fruquintinib and sintilimab for advanced endometrial cancer treatment

  This study is testing if a new combination of fruquintinib and sintilimab can help people with advanced endometrial cancer who didn't respond to their first treatment feel better compared to standard chemotherapy.

  Recruiting at 3 sites Phase 3 Hutchmed · Beijing, Beijing Municipality and 16 other locations · NCT06584032

• Combining sintilimab with chemotherapy for advanced NK/T-cell lymphoma

  This study is testing if adding a new drug called sintilimab to chemotherapy can help people with advanced NK/T-cell lymphoma do better than with chemotherapy alone.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06583083

• Using immune checkpoint inhibitors to preserve organs in non-metastatic gastric or colon cancers

  This study is testing a new combination of immune treatments to see if it can help people with non-metastatic gastric or colon cancers keep their organs and improve their health before surgery.

  Recruiting Phase 2 Peking University · Beijing, Beijing Municipality · NCT06580574

• Combining sintilimab with chemotherapy for treating esophageal cancer before surgery

  This study is testing if giving a new immunotherapy along with chemotherapy before surgery can help people with esophageal cancer have better outcomes.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06563869

• Triple therapy for patients with unresectable liver cancer

  This study is testing a new combination treatment for patients with hard-to-treat liver cancer to see if it can help shrink tumors more and improve survival rates.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian and 3 other locations · NCT06561399

• Sintilimab combined with chemoradiotherapy for elderly patients with advanced gastric cancer

  This study is testing if a new combination of a drug called sintilimab with chemotherapy and radiation can help older patients with advanced stomach cancer feel better and improve their quality of life.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06555471

• Combination therapy for advanced malignant peritoneal mesothelioma

  This study is testing a new combination of four medications to see if it can help people with advanced malignant peritoneal mesothelioma live longer and feel better.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06543069

• Combining hormone therapy and immunotherapy for advanced lung cancer

  This study is testing if combining hormone therapy with a type of immunotherapy can help older men with advanced lung cancer respond better to treatment.

  Recruiting Jinzhou Medical University · Zhengzhou, Henan · NCT06512207

• Combining Tucidinostat with Sintilimab and Bevacizumab for Colorectal Cancer

  This study is testing whether a new combination of three drugs can help people with a specific type of colorectal cancer live longer and feel better compared to a standard treatment.

  Recruiting Phase 3 Chipscreen Biosciences, Ltd. · Guangzhou, Guangdong · NCT06497985

• Combining immune therapy and chemotherapy for advanced head and neck cancer

  This study is testing if combining two immune therapies with chemotherapy can help people with advanced head and neck cancer have better treatment results before surgery.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT06494943

• Neoadjuvant therapy for HER2 positive locally advanced gastric cancer

  This study is testing a new treatment plan that combines radiation and medications to see if it can help people with advanced stomach cancer get ready for surgery.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06487429

• Combining Sintilimab with Chemotherapy for Esophageal Cancer Treatment

  This study is testing if combining a new drug called sintilimab with chemotherapy can help people with advanced esophageal cancer before surgery.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT06463834

• Combining Regorafenib, Sintilimab, and Electroacupuncture for Advanced Colorectal Cancer

  This study is testing a new treatment plan that combines two medications and electroacupuncture to see if it helps people with advanced colorectal cancer who haven't had success with previous chemotherapy.

  Recruiting The First People's Hospital of Changzhou · Changzhou · NCT06456515

• Combining Tafolecimab and Sintilimab with Chemotherapy for Advanced Lung Cancer

  This study is testing if combining two new drugs, Tafolecimab and Sintilimab, with chemotherapy can help people with advanced lung cancer who haven't had success with other treatments.

  Recruiting Phase 2 Beijing Chest Hospital, Capital Medical University · Beijing, Beijing Municipality · NCT06421298

• Using sintilimab after chemoradiotherapy for elderly patients with esophageal cancer

  This study is testing if adding a new treatment called sintilimab after chemotherapy and radiation can help older patients with esophageal cancer live longer and healthier.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06413342

• Using Fecal Microbiota Transplantation with Chemotherapy and Immunotherapy for Advanced Gastric Cancer

  This study is testing if adding a fecal microbiota transplant to chemotherapy and immunotherapy helps people with advanced gastric cancer live longer and feel better.

  Recruiting Phase 2 Changzhou No.2 People's Hospital · Changzhou · NCT06405113

• Combination treatment for advanced liver cancer

  This study is testing a new combination of treatments for advanced liver cancer to see if it helps patients live longer and feel better.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06397222

• Combining Fruquintinib, Regorafenib, and Sintilimab with Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new combination of three cancer drugs with or without radiation to see if it helps people with advanced colorectal cancer who have already tried other treatments.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06356584

• Immunotherapy with radiotherapy and nutrition support for advanced esophageal cancer in patients who can’t tolerate standard chemoradiation

  This trial tests whether adding a PD-1 inhibitor (sintilimab) to radiotherapy plus specialized nutrition helps patients with locally advanced esophageal squamous cell carcinoma who can’t tolerate standard chemoradiation.

  Recruiting at 10 sites Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 9 other locations · NCT06342167

• Combining Sintilimab with Chemoradiotherapy for Advanced Gastric Cancer

  This study is testing if combining an immunotherapy drug called Sintilimab with chemotherapy and radiotherapy can safely help people with advanced gastric cancer before surgery.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06341595

• Combination treatment for advanced gastric cancer

  This study is testing a new combination of treatments for people with advanced stomach cancer to see if it can help improve their health and fight the disease better.

  Recruiting Phase 1/2 Henan Cancer Hospital · Zhengzhou, Henan · NCT06329973

• Combination treatment for advanced liver cancer

  This study is testing a new combination of treatments for people with advanced liver cancer to see if it helps them live longer and feel better.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06244225

• Combining low-dose radiotherapy with sintilimab and temozolomide for recurrent glioblastoma

  This study is testing a new treatment that combines low-dose radiation with two medications to see if it can help people with recurrent glioblastoma feel better and improve their outcomes.

  Recruiting Phase 2 Fifth Affiliated Hospital, Sun Yat-Sen University · Zhuhai, Guangdong · NCT06220552

• Node-sparing radiotherapy with chemotherapy and immunotherapy for rectal cancer

  This study is testing a new way to treat locally advanced rectal cancer using targeted radiation, chemotherapy, and immunotherapy to see if it helps patients keep their organs and live longer.

  Recruiting Phase 2 Jinhua Central Hospital · Jinhua, Zhejiang · NCT06204094

• Using sintilimab after surgery for esophageal cancer

  This study tests if a medication called sintilimab can help prevent cancer from coming back in people who have had surgery for esophageal cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06190639

• Combining low-dose radiation with immunotherapy and chemotherapy for lung cancer treatment

  This study is testing if adding low-dose radiation to standard chemotherapy and a new immune treatment can help people with advanced lung cancer feel better and live longer.

  Recruiting at 6 sites Phase 2 Sichuan University · Chongqing, Chongqing Municipality and 5 other locations · NCT06121505

• Combination therapy for advanced gastric cancer with liver or lymph node metastasis

  This study is testing a new combination treatment for people with advanced gastric cancer that has spread to the liver or lymph nodes to see if it can help them become tumor-free before surgery.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjin · NCT06091423

• Neoadjuvant treatment for locally advanced gastric cancer using Sintilimab and chemotherapy

  This study is testing if a new combination of a drug called Sintilimab and chemotherapy can help people with locally advanced stomach cancer before surgery and improve their chances of recovery.

  Recruiting Phase 2 Huashan Hospital · Shanghai · NCT06054906

• Sintilimab combined with chemotherapy and radiotherapy for inoperable pancreatic cancer

  This study is testing if combining the immunotherapy drug Sintilimab with chemotherapy and radiotherapy can help people with inoperable pancreatic cancer live longer and feel better.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06050317

• Combining Sintilimab and Bevacizumab for Liver Cancer Patients with Blood Vessel Invasion

  This study is testing a new treatment combining two medications for people with advanced liver cancer and blood vessel invasion to see if it can help them live longer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06031285

• Comparing two treatment combinations for advanced liver cancer

  This study is testing two different treatment combinations for advanced liver cancer to see which one helps patients live longer after their first round of a specific procedure.

  Recruiting Phase 3 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05985798

• Combining Propranolol with Sintilimab and Chemotherapy for Advanced Lung Cancer

  This study is testing whether adding a heart medication called propranolol to a cancer drug and chemotherapy can help people with advanced lung cancer feel better and live longer.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT05979818

• Comparing two chemotherapy regimens for advanced gastric cancer treatment

  This study is testing whether a new combination of chemotherapy can help people with advanced stomach cancer live longer without their disease getting worse compared to the standard treatment.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 9 other locations · NCT05918094

• Combining radiotherapy with Surufatinib and Sintilimab for high-risk localized soft tissue sarcoma

  This study is testing a new treatment that combines radiotherapy with two medications, Surufatinib and Sintilimab, to see if it can help people with high-risk localized soft tissue sarcoma.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT05839275

• Comparing new drug combinations with standard treatment for advanced colorectal cancer

  This study is testing a new combination of drugs to see if it can help people with advanced colorectal cancer who didn’t respond to their first treatment live longer without their cancer getting worse, compared to the standard treatment.

  Recruiting Phase 3 Sun Yat-sen University · Hefei, Anhui and 11 other locations · NCT05768503

• Combining four drugs for treating unresectable gallbladder cancer

  This study is testing a combination of four drugs to see if it can help people with gallbladder cancer that can't be removed by surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT05757336

• Combining Sintilimab with Chemoradiotherapy for High-risk Nasopharyngeal Cancer

  This study is testing a new treatment plan that combines a cancer drug called Sintilimab with chemotherapy and radiation to see if it helps people with high-risk nasopharyngeal cancer.

  Recruiting Cancer Hospital of Guangxi Medical University · Nanning, Guangxi · NCT05707819

• Combining sintilimab and low-dose bevacizumab for treating relapsed oligodendroglioma

  This study is testing if a new combination of two drugs can help adults with relapsed oligodendroglioma live longer and feel better compared to standard treatment.

  Recruiting Phase 2 Henan Provincial People's Hospital · Zhengzhou, Henan · NCT05512351

• Using Sintilimab to treat advanced esophageal cancer after surgery

  This study is testing if the immunotherapy drug Sintilimab can help people with advanced esophageal cancer who are at high risk of their cancer coming back after surgery.

  Recruiting at 2 sites Phase 3 Henan Cancer Hospital · Zhengzhou, Henan and 1 other locations · NCT05495152

• Combination treatment for metastatic adenocarcinoma of the small intestine or appendix

  This study is testing a new combination of three medications to see if they can help people with advanced cancer of the small intestine or appendix who haven't responded to other treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05472948

• Combining chemoradiotherapy with sintilimab for advanced rectal cancer

  This study is testing if combining a new immunotherapy drug with standard treatment can help adults with advanced rectal cancer see better results and improve their health.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05450029

• Combining Sintilimab, Anlotinib, and Chemotherapy for Advanced Pleural Mesothelioma

  This study is testing a new combination of Sintilimab, Anlotinib, and chemotherapy to see if it helps people with advanced pleural mesothelioma who haven't had treatment before.

  Recruiting at 2 sites Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Taiyuan, Shanxi and 1 other locations · NCT05188859

• Neoadjuvant immunochemotherapy for advanced esophagogastric junction cancer

  This study is testing a new combination of immunotherapy and chemotherapy to see if it helps patients with advanced esophagogastric junction cancer before they have surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05170503

• Combination therapy for advanced high-grade neuroendocrine neoplasms

  This study is testing a new combination of three treatments to see if they can help people with advanced high-grade neuroendocrine tumors who haven't had success with standard therapies.

  Recruiting at 2 sites Phase 2 Peking University · Beijing, Beijing Municipality and 1 other locations · NCT05165407

• Cryoablation with Sintilimab and Lenvatinib for Liver Metastasis

  This study is testing whether combining a freezing treatment with two medications can help people with hard-to-treat liver cancer feel better after their previous treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05098847

• Combining sintilimab with reduced chemotherapy for oral cavity cancer treatment

  This study is testing if combining a new immune therapy called sintilimab with fewer chemotherapy sessions can help people with certain types of mouth cancer before they have surgery.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05098119

• Cryoablation with Sintilimab and Regorafenib for Liver Metastases from Colorectal Cancer

  This study is testing if combining a freezing treatment with two medications can help people with liver cancer from colorectal cancer who haven't responded to previous treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05057052

• Combining Lenvatinib and Sintilimab for Advanced Liver Cancer After Previous Treatment

  This study is testing if combining two medications, Lenvatinib and Sintilimab, can help people with advanced liver cancer who have already tried other treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05010681

• Preoperative treatment for salivary gland cancer using Sintilimab, Carboplatin, and Nab-paclitaxel

  This study is testing a new treatment using Sintilimab, carboplatin, and nab-paclitaxel before surgery to see if it can help people with salivary gland cancer by boosting their immune response and shrinking the tumors.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05000892

• Combination of chemotherapy and immunotherapy for advanced esophagogastric junction cancer

  This study is testing if combining a new immune therapy with chemotherapy can help people with advanced esophagogastric junction cancer have smaller tumors that are easier to remove and improve their chances of living longer.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT04989985

• Combining sintilimab, bevacizumab, and chemotherapy for lung cancer treatment before surgery

  This study is testing a new treatment that combines two medications and chemotherapy before surgery to see if it helps people with advanced lung cancer.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT04973293

• Combining orelabrutinib and sintilimab for treating relapsed central nervous system lymphoma

  This study is testing a combination of two drugs, orelabrutinib and sintilimab, to see if they can help people with relapsed central nervous system lymphoma feel better.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT04961515

• Monitoring the safety of Sintilimab in Chinese patients

  This study is testing how safe Sintilimab is for Chinese patients by closely watching for any side effects while they receive the treatment.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT04840355

• Neoadjuvant immunotherapy for stage III non-small cell lung cancer

  This study is testing a new treatment using a drug called Sintilimab, with or without chemotherapy, to see if it can shrink tumors in patients with stage III non-small cell lung cancer before they have surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT04728724

• Combining Sintilimab and Chidamide for treating Peripheral T-cell Lymphoma

  This study is testing a new treatment combining Sintilimab and Chidamide to see if it can help people with relapsed or hard-to-treat peripheral T-cell lymphoma feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT04512534

Quick answers

How many clinical trials of Sintilimab are recruiting right now?

124, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 86, Phase 3: 16, Phase 1/2: 7, Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →